Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DOCS Doximity	$52.06 +2.0%	$55.91	$25.00 ▼ $85.21	$9.72B	1.41	2.10 million shs	1.52 million shs
MASI Masimo	$157.25 +4.7%	$157.73	$101.61 ▼ $194.88	$8.53B	1.23	651,722 shs	690,633 shs
RETA Reata Pharmaceuticals	$172.36	$171.30	$21.83 ▼ $172.46	$6.58B	1.42	1.09 million shs	N/A
TXG 10x Genomics	$8.59 +5.1%	$8.52	$6.78 ▼ $24.76	$1.06B	1.94	2.39 million shs	2.65 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DOCS Doximity	+1.95%	-1.79%	-8.14%	-28.60%	+87.06%
MASI Masimo	+4.74%	+0.69%	-3.96%	-17.38%	+23.82%
RETA Reata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
TXG 10x Genomics	+5.14%	-5.40%	+3.49%	-26.27%	-61.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DOCS Doximity	3.2894 of 5 stars	3.3	0.0	0.0	0.0	3.2	4.2	1.3
MASI Masimo	4.5578 of 5 stars	3.4	3.0	0.0	4.2	4.1	2.5	1.3
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	4.3483 of 5 stars	4.2	1.0	0.0	4.8	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DOCS Doximity	2.57	Moderate Buy	$61.89	18.88% Upside
MASI Masimo	2.83	Moderate Buy	$191.60	21.84% Upside
RETA Reata Pharmaceuticals	0.00	N/A	N/A	N/A
TXG 10x Genomics	2.38	Hold	$15.81	84.02% Upside

Current Analyst Ratings Breakdown

Latest DOCS, MASI, TXG, and RETA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	DOCS Doximity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$63.00 ➝ $60.00
5/24/2025	TXG 10x Genomics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/21/2025	DOCS Doximity	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$80.00 ➝ $50.00
5/20/2025	DOCS Doximity	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$87.00 ➝ $65.00
5/19/2025	TXG 10x Genomics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $18.00
5/16/2025	DOCS Doximity	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$58.00 ➝ $52.00
5/16/2025	DOCS Doximity	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$65.00 ➝ $60.00
5/16/2025	DOCS Doximity	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$83.00 ➝ $65.00
5/16/2025	DOCS Doximity	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	DOCS Doximity	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$71.00 ➝ $50.00
5/16/2025	DOCS Doximity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$82.00 ➝ $67.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DOCS Doximity	$570.40M	17.04	$0.64 per share	81.32	$5.52 per share	9.43
MASI Masimo	$2.13B	4.01	$5.12 per share	30.74	$25.79 per share	6.10
RETA Reata Pharmaceuticals	$23.48M	280.05	N/A	N/A	($1.79) per share	-96.29
TXG 10x Genomics	$624.66M	1.69	N/A	N/A	$5.81 per share	1.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DOCS Doximity	$147.58M	$1.11	52.06	48.65	4.10	36.60%	21.75%	18.64%	N/A
MASI Masimo	$81.50M	-$9.17	108.45	33.96	N/A	3.85%	14.98%	6.95%	8/5/2025 (Estimated)
RETA Reata Pharmaceuticals	-$311.90M	N/A	0.00	N/A	N/A	N/A	-922.50%	-73.39%	N/A
TXG 10x Genomics	-$182.63M	-$1.30	N/A	N/A	N/A	-29.90%	-25.40%	-19.69%	8/14/2025 (Estimated)

Latest DOCS, MASI, TXG, and RETA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	N/A	DOCS Doximity	$0.27	$0.38	+$0.11	N/A	N/A	N/A
5/8/2025	Q1 2025	TXG 10x Genomics	-$0.45	-$0.36	+$0.09	-$0.28	$131.91 million	$154.88 million
5/6/2025	Q1 2025	MASI Masimo	$1.24	$1.36	+$0.12	-$3.12	$367.79 million	$372.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DOCS Doximity	N/A	N/A	N/A	N/A	N/A
MASI Masimo	N/A	N/A	N/A	N/A	N/A
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DOCS Doximity	N/A	8.74	8.74
MASI Masimo	0.50	2.01	1.11
RETA Reata Pharmaceuticals	0.84	3.21	3.19
TXG 10x Genomics	N/A	4.97	4.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DOCS Doximity	87.19%
MASI Masimo	85.96%
RETA Reata Pharmaceuticals	N/A
TXG 10x Genomics	84.68%

Insider Ownership

Company	Insider Ownership
DOCS Doximity	37.40%
MASI Masimo	9.70%
RETA Reata Pharmaceuticals	26.80%
TXG 10x Genomics	9.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DOCS Doximity	890	186.69 million	116.87 million	Not Optionable
MASI Masimo	6,200	54.22 million	48.35 million	Optionable
RETA Reata Pharmaceuticals	321	38.15 million	27.93 million	Optionable
TXG 10x Genomics	1,240	123.13 million	108.91 million	Optionable

DOCS, MASI, TXG, and RETA Headlines

Recent News About These Companies

Weiss Ratings Reiterates "Sell (E+)" Rating for 10x Genomics (NASDAQ:TXG)

May 27 at 4:35 AM | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Earns Sell (E+) Rating from Weiss Ratings

May 27 at 3:53 AM | americanbankingnews.com

Squarepoint Ops LLC Sells 121,729 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

May 26 at 4:36 AM | marketbeat.com

10x Genomics, Inc. (NASDAQ:TXG) Shares Purchased by Man Group plc

May 26 at 3:58 AM | marketbeat.com

10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Bank of America Corp DE

May 26 at 3:21 AM | marketbeat.com

Voloridge Investment Management LLC Boosts Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

May 25 at 4:55 AM | marketbeat.com

Two Sigma Investments LP Has $18.95 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

May 25 at 4:23 AM | marketbeat.com

10x Genomics (NASDAQ:TXG) Upgraded by Wall Street Zen to Buy Rating

May 24, 2025 | marketbeat.com

10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Two Sigma Advisers LP

May 24, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $2.29 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG)

May 24, 2025 | marketbeat.com

Why 10x Genomics Stock Was Sliding This Week

May 23, 2025 | msn.com

Quantinno Capital Management LP Has $2.15 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

May 23, 2025 | marketbeat.com

10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know

May 21, 2025 | zacks.com

10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Northern Trust Corp

May 21, 2025 | marketbeat.com

Morgan Stanley Lowers 10x Genomics (NASDAQ:TXG) Price Target to $18.00

May 21, 2025 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Shares Down 4.8% on Analyst Downgrade

May 21, 2025 | americanbankingnews.com

Jacobs Levy Equity Management Inc. Buys Shares of 31,367 10x Genomics, Inc. (NASDAQ:TXG)

May 20, 2025 | marketbeat.com

Jefferies Financial Group Inc. Has $446,000 Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

May 19, 2025 | marketbeat.com

10x Genomics' (TXG) "Overweight" Rating Reiterated at Stephens

May 18, 2025 | americanbankingnews.com

Numerai GP LLC Has $2.27 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG)

May 16, 2025 | marketbeat.com

Cresset Asset Management LLC Cuts Position in 10x Genomics, Inc. (NASDAQ:TXG)

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS, MASI, TXG, and RETA Company Descriptions

Doximity NASDAQ:DOCS

$52.06 +1.04 (+2.04%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$51.81 -0.25 (-0.49%)

As of 05/27/2025 07:57 PM Eastern

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Masimo NASDAQ:MASI

$157.25 +7.12 (+4.74%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$157.22 -0.03 (-0.02%)

As of 05/27/2025 06:06 PM Eastern

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

10x Genomics NASDAQ:TXG

$8.59 +0.42 (+5.14%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$8.66 +0.07 (+0.80%)

As of 05/27/2025 07:42 PM Eastern

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time